Literature DB >> 9933127

Update: recommendations to prevent hepatitis B virus transmission--United States.

.   

Abstract

In October 1997, the Advisory Committee on Immunization Practices (ACIP) expanded its hepatitis B vaccination recommendations to include all unvaccinated children aged 0-18 years and made hepatitis B vaccine available through the Vaccines for Children program (VFC) for persons aged 0-18 years who are eligible for VFC. ACIP priorities for hepatitis B vaccination of children remain unchanged and include all infants; children in populations at high risk for hepatitis B virus (HBV) infection (e.g., Alaska Natives, Pacific Islanders, and children who reside in households of first-generation immigrants from countries where HBV infection is moderately or highly endemic); previously unvaccinated children aged 11-12 years; and older adolescents and adults in defined risk groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933127

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  31 in total

1.  Hepatitis B immunization coverage among Vietnamese-American children 3 to 18 years old.

Authors:  C N Jenkins; S J McPhee; C Wong; T Nguyen; G L Euler
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

2.  Hepatitis B vaccination among adolescents 13-17 years, United States, 2006-2012.

Authors:  Peng-jun Lu; David Yankey; Jenny Jeyarajah; Alissa O'Halloran; Laurie Elam-Evans; Stacie M Greby; James A Singleton; Trudy V Murphy
Journal:  Vaccine       Date:  2015-02-25       Impact factor: 3.641

3.  Trends in Prevalence of Protective Levels of Hepatitis B Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus Infection-United States, 2003-2014.

Authors:  Hope King; Jian Xing; Hazel D Dean; Deborah Holtzman
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

4.  Hepatitis B vaccination coverage among health-care personnel in the United States.

Authors:  Kathy K Byrd; Peng-jun Lu; Trudy V Murphy
Journal:  Public Health Rep       Date:  2013 Nov-Dec       Impact factor: 2.792

5.  Hepatitis A and Hepatitis B Vaccination Coverage Among Persons Who Inject Drugs and Have Evidence of Hepatitis C Infection.

Authors:  Ruth Koepke; Danielle N Sill; Wajiha Z Akhtar; Kailynn P Mitchell; Sheila M Guilfoyle; Ryan P Westergaard; Stephanie L Schauer; James M Vergeront
Journal:  Public Health Rep       Date:  2019-09-20       Impact factor: 2.792

6.  Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease.

Authors:  Xin Yue; Carla L Black; Alissa O'Halloran; Peng-Jun Lu; Walter W Williams; Noele P Nelson
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

Review 7.  Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications.

Authors:  Shaili Gupta; Frederick L Altice
Journal:  J Urban Health       Date:  2009-01-28       Impact factor: 3.671

8.  Positive impact of a shelter-based hepatitis B vaccine program in homeless Baltimore children and adolescents.

Authors:  Kathleen Schwarz; Beth Garrett; Jennifer Lee; Douglas Thompson; Thelma Thiel; Miriam J Alter; Stephanie Strathdee
Journal:  J Urban Health       Date:  2008-02-15       Impact factor: 3.671

9.  Successful promotion of hepatitis B vaccinations among Vietnamese-American children ages 3 to 18: results of a controlled trial.

Authors:  Stephen J McPhee; Thoa Nguyen; Gary L Euler; Jeremiah Mock; Ching Wong; Tram Lam; Walter Nguyen; Sang Nguyen; Martin Quach Huynh Ha; Son T Do; Chau Buu
Journal:  Pediatrics       Date:  2003-06       Impact factor: 7.124

10.  Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States.

Authors:  Karen A Hennessey; Andrea A Kim; Vivian Griffin; Nicoline T Collins; Cindy M Weinbaum; Keith Sabin
Journal:  J Urban Health       Date:  2008-07-12       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.